首页> 外文期刊>Vascular Health and Risk Management >Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy
【24h】

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy

机译:与阿托伐他汀单药治疗相比,烟酸缓释/辛伐他汀联合治疗对高密度脂蛋白颗粒产生更大的有利变化

获取原文
           

摘要

Background: The purpose of this research was to compare the effects of niacin extended-release in combination with simvastatin (NER/S) versus atorvastatin monotherapy on high-density lipoprotein (HDL) particle number and size in patients with hyperlipidemia or dyslipidemia from the SUPREME study. Methods: This was a post hoc analysis of patients (n = 137) who completed the SUPREME study and who had lipid particle number and size measurements at both baseline and at week 12 by nuclear magnetic resonance spectroscopy. Following ≥4 weeks without lipid-modifying therapy (washout period), the patients received NER/S 1000/40 mg/day for 4 weeks followed by NER/S 2000/40 mg/day for 8 weeks, or atorvastatin 40 mg/day for 12 weeks. Median percent changes in HDL particle number and size from baseline to week 12 were compared between the NER/S and atorvastatin treatment groups using the Wilcoxon rank-sum test. Distribution of HDL particle subclasses at week 12 was compared between the treatment groups using the Cochran–Mantel–Haenszel test. Results: Treatment with NER/S resulted in a significantly greater percent reduction in small HDL particle number at week 12 compared with atorvastatin monotherapy (-1.8% versus 4.2%, P = 0.014), and a numerically greater percent increase in large HDL particle number (102.4% versus 39.2%, P = 0.078) compared with atorvastatin monotherapy. A significantly greater percent increase in HDL particle size from baseline at week 12 was observed with NER/S compared with atorvastatin (6.0% versus 1.3%, P < 0.001). NER/S treatment also resulted in a significant shift in HDL particle size from small and medium at baseline to large at week 12 ( P < 0.0001). Conclusion: Treatment with NER/S resulted in larger favorable changes in number and size of HDL particle subclasses compared with atorvastatin monotherapy, including a numerically greater increase in number of large HDL particles, and a significantly greater decrease in number of small HDL particles compared with atorvastatin monotherapy. In addition, NER/S treatment resulted in a significant change in HDL particle size distribution from small and medium to large.
机译:背景:本研究的目的是比较烟酸缓释联合辛伐他汀(NER / S)与阿托伐他汀单药治疗对SUPREME高脂血症或血脂异常患者高密度脂蛋白(HDL)颗粒数量和大小的影响研究。方法:这是对完成SUPREME研究且在基线和第12周通过核磁共振波谱测量脂质颗粒数量和大小的患者(n = 137)的事后分析。 ≥4周未进行脂质修饰治疗(清除期)后,患者接受NER / S 1000/40 mg /天,共4周,然后接受NER / S 2000/40 mg /天,共8周,或阿托伐他汀40 mg /天持续12周。使用Wilcoxon秩和检验比较了NER / S和阿托伐他汀治疗组之间从基线到第12周HDL颗粒数量和大小的中位数变化百分比。使用Cochran–Mantel–Haenszel检验比较了各治疗组在第12周时HDL颗粒亚类的分布。结果:与阿托伐他汀单药治疗相比,用NER / S治疗导致在12周时小HDL颗粒数量的减少百分比显着更大(-1.8%对4.2%,P = 0.014),大HDL颗粒数量的增加百分比在数值上与阿托伐他汀单一疗法相比(分别为102.4%和39.2%,P = 0.078)。与阿托伐他汀相比,与阿托伐他汀相比,NER / S观察到HDL粒径较基线在12周时有明显增加的百分比(6.0%比1.3%,P <0.001)。 NER / S处理还导致HDL粒径从基线的中小值显着转变为第12周的大值(P <0.0001)。结论:与阿托伐他汀单药治疗相比,NER / S治疗导致HDL颗粒亚类的数量和大小发生了较大的有利变化,包括与大剂量HDL颗粒相比,在数量上增加了更多的数字,而与之相比,小的HDL颗粒数量显着减少了阿托伐他汀单一疗法。此外,NER / S处理导致HDL粒度分布从大中小发生了很大变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号